Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk
The introduction of selective cyclooxygenase‐2 inhibitors offered the promise of similar efficacy in pain control without the gastrointestinal effects associated with non‐selective non‐steroidal anti‐inflammatory drugs (NSAIDs). By blocking prostacyclin formation but leaving platelet‐derived thrombo...
Saved in:
Published in | Internal medicine journal Vol. 36; no. 5; pp. 308 - 319 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Melbourne, Australia
Blackwell Publishing Asia
01.05.2006
Blackwell Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The introduction of selective cyclooxygenase‐2 inhibitors offered the promise of similar efficacy in pain control without the gastrointestinal effects associated with non‐selective non‐steroidal anti‐inflammatory drugs (NSAIDs). By blocking prostacyclin formation but leaving platelet‐derived thromboxane A2 generation unopposed, there is concern that the potential gastrointestinal benefit of cyclooxygenase‐2‐selective inhibitors may come at the cost of increased thrombotic risk. However, the differential effects of coxibs on blood pressure, endothelial function, oxidative stress, tissue factor expression, vascular smooth muscle proliferation and neointimal hyperplasia indicate a distinct heterogeneity among this class of drugs. Importantly, the observation of an excess cardiovascular risk with traditional NSAIDs in randomized clinical trials, meta‐analysis and large‐scale observational studies further highlights the need to scrutinize the entire class of anti‐inflammatory drugs, including traditional NSAIDs, as rigorously as coxibs. |
---|---|
Bibliography: | ark:/67375/WNG-X4MJTXPK-3 istex:28D1183525E968E6B6AB4139BECB2B25F646FED5 ArticleID:IMJ1056 Funding: None Potential conflicts of interest: Dr Ruschitzka has served as a consultant or received speaker fees from Aventis, Bayer, Merck, Novartis and Pfizer. |
ISSN: | 1444-0903 1445-5994 |
DOI: | 10.1111/j.1445-5994.2006.01056.x |